KAZIA THERAPEUTICS LTD
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filer
State of Incorporation
Australia
Country
Australia
Business Address
THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, , 2000
Mailing Address
THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, , 2000
Phone
01161298780088
Fiscal Year End
0630
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 15, 2026 | View on SEC |
| 6-K Foreign company current report | April 13, 2026 | View on SEC |
| 3 Initial insider ownership report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
November 7, 2025
- FDA granted paxalisib 'Fast Track' status to expedite reviews.
- Partnered with St. Jude’s Hospital to share trial costs.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.